摘要
目的:观察β片层阻断肽H102-BD经鼻腔给药后对PAP双转基因阿尔茨海默病(AD)模型小鼠行为学、脑内APP及Aβ蛋白表达的影响。方法:将PAP转基因小鼠随机分为模型组和H102-BD给药组,并设同月龄同背景C57BL/6J小鼠为正常对照组。鼻腔给药4周后行Morris水迷宫实验,利用免疫组织化学方法和Western blot方法测定小鼠脑内APP和Aβ蛋白的表达。结果:(1)Morris水迷宫结果显示鼻腔给予H102-BD后AD模型鼠的空间记忆能力有了明显的提高。(2)免疫组化及Western blot结果显示,H102-BD可显著降低AD模型鼠脑内APP及Aβ蛋白表达。结论:β片层阻断肽H102-BD经鼻腔给药后对AD有一定的治疗作用。
Objective： To investigate the effect of H102-BD on behavior and the expression of APP and Aβ in PAP transgenic AD mice after intranasal administration. Methods： The PAP transgenic mice were randomly divided into model group and H102-BD treatment group, and a group of C57BL/6J mice with the same age and background was set as normal. After intranasal administration for four weeks, the ability of spatial reference memory was tested by Morris Water Maze, and then the immunohistochemical stain and Western blot were carried out to detect the content of APP and Aβ in mice brain. Results： （1） The memory of H102-BD group was significantly improved compared with that in model group by the test of Morris Water Maze. （2） The contents of APP and Aβ were significantly decreased in H102-BD group compared with those in model group by the test of immunohistochemical stain and Western blot. Conclusion： β-sheet breaker H102-BD may be an effective therapeutic strategy for AD after intranasal administration.
作者
孙凤仙
徐淑梅
SUN Feng-xian XU Shu-mei(Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, Chin)
出处
《天津医科大学学报》
2017年第5期385-388,共4页
Journal of Tianjin Medical University
基金
国家科技重大专项基金资助(2009ZX09103-029)
天津市科技计划项目(16YFZCSY01000)
